Business Context and Reporting Period
This Form 8-K is a current report filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) on September 20, 2016. The filing addresses corporate governance changes, specifically the departure of a director and subsequent committee reassignments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Director Resignation: William H. Nelson resigned as an independent director and from all Board committee positions (Chairman of Nomination and Corporate Governance; member of Audit and Compensation Committees), effective immediately.
- Reason for Departure: The resignation was not the result of any disagreement with the Company regarding operations, policies, or practices.
- Board Composition: The Board size decreased from six to five members.
- Committee Reassignments:
- Anthony Principi (current independent director) was added to the Audit Committee and appointed Chairman of the Nomination and Corporate Governance Committee.
- Stephen Austin (current independent director) was added to the Compensation Committee.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies. The only unusual item noted is the reduction in Board size.
Investor Verification Checklist
- Verify the updated composition of the Board of Directors and committee memberships.
- Confirm that the resignation of William H. Nelson was not indicative of undisclosed internal conflicts.
- Review subsequent filings for any impact of the reduced Board size on corporate governance or strategic direction.